[Form 4] GRI Bio, Inc. Insider Trading Activity
GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.
GRI Bio, Inc. (GRI) riferisce una Sezione 16 Form 4 per Vipin Chaturvedi, Chief Scientific Officer, che mostra una concessione di stock option il 09/18/2025. Il derivato riportato è un'opzione su azioni con un prezzo di esercizio di $1.93 che copre 43,222 azioni ordinarie. Di tali opzioni, 29,923 si sono valse integralmente al momento della concessione e 13,299 matureranno in 12 rate trimestrali sostanzialmente uguali, con piena maturazione al terzo anniversario della concessione. Le opzioni sono esercitabili fino al 09/18/2035. Il Form 4 elenca 43,222 azioni sottostanti beneficiariamente possedute dopo la transazione e indica la proprietà diretta. Il deposito è firmato da Leanne Kelly, Attorney-in-Fact, datato 09/22/2025.
GRI Bio, Inc. (GRI) reporta un Formulario 4 de la Sección 16 para Vipin Chaturvedi, Director Científico, mostrando una concesión de opción de compra de acciones el 09/18/2025. El derivado reportado es una opción de compra de acciones con un precio de ejercicio de $1.93 que cubre 43,222 acciones ordinarias. De esas opciones, 29,923 adquirieron derechos por completo en la fecha de concesión y 13,299 se ejercitarán en 12 cuotas trimestrales sustancialmente iguales, con adquisición total al tercer aniversario de la concesión. Las opciones son exercibles hasta el 09/18/2035. El Form 4 lista 43,222 acciones subyacentes de propiedad beneficiaria tras la transacción e indica propiedad directa. La presentación está firmada por Leanne Kelly, Attorney-in-Fact, con fecha 09/22/2025.
GRI Bio, Inc. (GRI)가 Vipin Chaturvedi, Chief Scientific Officer를 위한 제16조 Form 4를 보고하며 09/18/2025에 주식매수선택권 부여를 보여줍니다. 보고된 파생상품은 행사가격이 $1.93인 주식매수선택권으로 43,222주의 보통주를 커버합니다. 그 중 29,923주가 부여일에 전액 vest되었고 13,299주는 Grant의 세 번째 기념일까지 거의 같은 12개의 분할로 vesting되며, 세 번째 기념일에 완전 vesting됩니다. 그 옵션은 09/18/2035까지 행사 가능합니다. Form 4는 거래 후 실질적으로 소유된 기초주식 43,222주를 기재하고 직접 소유를 나타냅니다. 제출은 Leanne Kelly, Attorney-in-Fact가 서명했으며 날짜는 09/22/2025입니다.
GRI Bio, Inc. (GRI) déclare un Formulaire 4 de la Section 16 pour Vipin Chaturvedi, Directeur Scientifique en Chef, affichant une attribution d’option d’achat d’actions le 09/18/2025. Le dérivé déclaré est une option d’achat d’actions avec un prix d’exercice de $1.93 couvrant 43,222 actions ordinaires. Sur ces options, 29,923 ont acquis pleinement leurs droits à la date de la concession et 13,299 seront acquises en 12 versements trimestriels sensiblement équivalents, devenant entièrement vénus at les au cours du troisième anniversaire de la concession. Les options peuvent être exercées jusqu’au 09/18/2035. Le Form 4 indique 43,222 actions sous-jacentes détenues après la transaction et indique une propriété directe. Le dépôt est signé par Leanne Kelly, Attorney-in-Fact, daté du 09/22/2025.
GRI Bio, Inc. (GRI) meldet ein Section 16 Form 4 für Vipin Chaturvedi, Chief Scientific Officer, das eine Gewährung von Aktienoptionen am 09/18/2025 zeigt. Das berichtete Derivat ist eine Aktienoption mit einem Ausübungspreis von $1.93 und deckt 43,222 Stammaktien ab. Davon haben 29,923 am Gewährungsdatum vollständig vestet und 13,299 werden in 12 im Wesentlichen gleichen vierteljährlichen Raten vesten, vollständig mit dem dritten Jahrestag der Gewährung vestend. Die Optionen sind bis zum 09/18/2035 ausübbar. Das Form 4 listet 43,222 zugrunde liegende Aktien auf, die nach der Transaktion vorteilhaft gehalten werden, und weist auf direkte Eigentümerschaft hin. Die Einreichung wird von Leanne Kelly, Attorney-in-Fact, datiert auf 09/22/2025 unterzeichnet.
GRI Bio, Inc. (GRI) تقر بتقديم نموذج Form 4 القسم 16 للسيد فيبن تشاتورفيدي، كبير المسؤولين العلميّين، يعرض منحة خيار أسهم في 09/18/2025. المشتق المبلغ عنه هو خيار أسهم بسعر ممارسة قدره $1.93 يغطي 43,222 سهمًا من الأسهم العادية. من بين تلك الخيارات، تم vesting 29,923 بالكامل في تاريخ المنحة و 13,299 ستتوزع على 12 قسطًا ربع سنويًا تقريبا بالتساوي، وتكتمل vesting في الذكرى الثالثة لمنحة. الخيارات قابلة للممارسة حتى 09/18/2035. يسرد Form 4 43,222 من الأسهم الأساسية المملوكة بشكل مستفيد بعد المعاملة ويشير إلى الملكية المباشرة. مرفق التقديم موقع من قبل Leanne Kelly، وكيلة قانونية، بتاريخ 09/22/2025 توقيع.
GRI Bio, Inc. (GRI) 就 Vipin Chaturvedi，首席科学官，提交了第16节 Form 4，显示于 09/18/2025 授予一项股票期权。所报导的衍生工具为行使价格为 $1.93 的股票期权，覆盖 43,222 股普通股。其中 29,923 股在授予日已完全归属，13,299 将在 12 个基本等额的季度分期 vest，直到授予的第三周年完全归属。该期权可在 09/18/2035 前行使。Form 4 列出在交易后最终受益所有的底层股票 43,222 股，并指出为直接所有权。该备案由 Leanne Kelly，代理人，日期为 09/22/2025 签名。
- Immediate vesting of 29,923 options aligns executive incentives with shareholder interests upon grant
- Clear vesting schedule for the remaining 13,299 options (12 quarterly installments, fully vested in three years)
- Full disclosure of exercise price ($1.93), option quantity (43,222), and expiration date (09/18/2035)
- None.
Insights
TL;DR: Routine executive option grant with immediate partial vesting; limited direct ownership disclosure.
The Form 4 documents a standard equity compensation event: a stock option grant to the Chief Scientific Officer for 43,222 shares at a $1.93 exercise price, with 29,923 shares fully vested at grant and the remainder vesting quarterly over three years. The option term extends ten years to 09/18/2035 and is reported as direct ownership. This disclosure informs investors about insider alignment via equity incentives and updates outstanding insider-held options but contains no cash, revenue, or debt information.
TL;DR: Compensation structure mixes immediate vesting and time-based vesting to retain key executive.
The grant structure—majority vested on grant with the balance vesting over 12 quarterly installments—combines immediate reward with continued service incentives. The filing clearly states exercisability and expiration dates and identifies the reporting person as the Chief Scientific Officer, meeting Section 16 reporting requirements. The Form 4 is administrative and does not disclose plan-level authorizations or aggregate insider holdings beyond this transaction.
GRI Bio, Inc. (GRI) riferisce una Sezione 16 Form 4 per Vipin Chaturvedi, Chief Scientific Officer, che mostra una concessione di stock option il 09/18/2025. Il derivato riportato è un'opzione su azioni con un prezzo di esercizio di $1.93 che copre 43,222 azioni ordinarie. Di tali opzioni, 29,923 si sono valse integralmente al momento della concessione e 13,299 matureranno in 12 rate trimestrali sostanzialmente uguali, con piena maturazione al terzo anniversario della concessione. Le opzioni sono esercitabili fino al 09/18/2035. Il Form 4 elenca 43,222 azioni sottostanti beneficiariamente possedute dopo la transazione e indica la proprietà diretta. Il deposito è firmato da Leanne Kelly, Attorney-in-Fact, datato 09/22/2025.
GRI Bio, Inc. (GRI) reporta un Formulario 4 de la Sección 16 para Vipin Chaturvedi, Director Científico, mostrando una concesión de opción de compra de acciones el 09/18/2025. El derivado reportado es una opción de compra de acciones con un precio de ejercicio de $1.93 que cubre 43,222 acciones ordinarias. De esas opciones, 29,923 adquirieron derechos por completo en la fecha de concesión y 13,299 se ejercitarán en 12 cuotas trimestrales sustancialmente iguales, con adquisición total al tercer aniversario de la concesión. Las opciones son exercibles hasta el 09/18/2035. El Form 4 lista 43,222 acciones subyacentes de propiedad beneficiaria tras la transacción e indica propiedad directa. La presentación está firmada por Leanne Kelly, Attorney-in-Fact, con fecha 09/22/2025.
GRI Bio, Inc. (GRI)가 Vipin Chaturvedi, Chief Scientific Officer를 위한 제16조 Form 4를 보고하며 09/18/2025에 주식매수선택권 부여를 보여줍니다. 보고된 파생상품은 행사가격이 $1.93인 주식매수선택권으로 43,222주의 보통주를 커버합니다. 그 중 29,923주가 부여일에 전액 vest되었고 13,299주는 Grant의 세 번째 기념일까지 거의 같은 12개의 분할로 vesting되며, 세 번째 기념일에 완전 vesting됩니다. 그 옵션은 09/18/2035까지 행사 가능합니다. Form 4는 거래 후 실질적으로 소유된 기초주식 43,222주를 기재하고 직접 소유를 나타냅니다. 제출은 Leanne Kelly, Attorney-in-Fact가 서명했으며 날짜는 09/22/2025입니다.
GRI Bio, Inc. (GRI) déclare un Formulaire 4 de la Section 16 pour Vipin Chaturvedi, Directeur Scientifique en Chef, affichant une attribution d’option d’achat d’actions le 09/18/2025. Le dérivé déclaré est une option d’achat d’actions avec un prix d’exercice de $1.93 couvrant 43,222 actions ordinaires. Sur ces options, 29,923 ont acquis pleinement leurs droits à la date de la concession et 13,299 seront acquises en 12 versements trimestriels sensiblement équivalents, devenant entièrement vénus at les au cours du troisième anniversaire de la concession. Les options peuvent être exercées jusqu’au 09/18/2035. Le Form 4 indique 43,222 actions sous-jacentes détenues après la transaction et indique une propriété directe. Le dépôt est signé par Leanne Kelly, Attorney-in-Fact, daté du 09/22/2025.
GRI Bio, Inc. (GRI) meldet ein Section 16 Form 4 für Vipin Chaturvedi, Chief Scientific Officer, das eine Gewährung von Aktienoptionen am 09/18/2025 zeigt. Das berichtete Derivat ist eine Aktienoption mit einem Ausübungspreis von $1.93 und deckt 43,222 Stammaktien ab. Davon haben 29,923 am Gewährungsdatum vollständig vestet und 13,299 werden in 12 im Wesentlichen gleichen vierteljährlichen Raten vesten, vollständig mit dem dritten Jahrestag der Gewährung vestend. Die Optionen sind bis zum 09/18/2035 ausübbar. Das Form 4 listet 43,222 zugrunde liegende Aktien auf, die nach der Transaktion vorteilhaft gehalten werden, und weist auf direkte Eigentümerschaft hin. Die Einreichung wird von Leanne Kelly, Attorney-in-Fact, datiert auf 09/22/2025 unterzeichnet.
FAQ
What transaction did Vipin Chaturvedi report on Form 4 for GRI?
How many of the granted options vested immediately for GRI insider Vipin Chaturvedi?
What is the expiration date and exercisability period for the options reported by GRI?
Does the Form 4 indicate whether the reported ownership is direct or indirect for Vipin Chaturvedi?
Who signed the Form 4 for the GRI filing and when?
